AKTX

Akari Therapeutics, Plc (AKTX) ESG Analysis Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.4 (Moderate)

AKTX shows limited disclosed environmental intensity metrics, leaving its peer-relative footprint harder to verify than larger biotech peers with more complete sustainability reporting.

The company’s low leverage reduces balance-sheet pressure that can otherwise constrain environmental compliance spending, but this is a weaker differentiator than direct emissions or waste disclosure.

With no reported R&D-to-revenue intensity in the provided metrics, environmental resource-use efficiency cannot be benchmarked well against peers, limiting confidence in relative positioning.

Overall environmental positioning appears broadly average to slightly below transparent peers because disclosure depth, not evidence of major environmental harm, is the main constraint.

Social

Score:

AKTX’s social profile is difficult to assess peer-relatively because the provided data do not show workforce, safety, or patient-access indicators that typically drive biotech social risk.

Zero stock-based compensation in the supplied metrics suggests less dilution-linked employee incentive pressure than many peers, but it does not establish stronger broader social practices.

As a small-cap biotech, AKTX likely faces higher dependence on specialized talent than diversified peers, yet the available evidence does not show a clear labor-practice disadvantage.

Social positioning is therefore moderate, with limited disclosure preventing a stronger peer comparison despite no visible sign of acute social controversy.

Governance

Score:

AKTX’s very low debt-to-equity ratio indicates restrained financial leverage, which can reduce creditor influence and support cleaner governance than more levered peers.

The absence of stock-based compensation in the provided metrics suggests less shareholder dilution pressure than peers that rely heavily on equity incentives.

However, the available data do not disclose board independence, audit quality, or shareholder-rights practices, which limits confidence in a stronger governance ranking.

Governance appears modestly better than highly levered small-cap peers, but incomplete disclosure keeps it below the stronger end of the peer set.

Overall Score

Score:

AKTX’s ESG positioning is moderate versus peers because low leverage and limited dilution support governance, while sparse disclosure constrains confidence across all three pillars.

Score Driver: Limited ESG Disclosure Depth Relative To Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Akari Therapeutics, Plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →